Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
consortium, Capacity-Covid collaborative, Group, Leoss Study, Linschoten, M.; Uijl, A.; Schut, A.; Jakob, C. E. M.; Romão, L. R.; Bell, R. M.; McFarlane, E.; Stecher, M.; Zondag, A. G. M.; van Iperen, E. P. A.; Hermans-van Ast, W.; Lea, N. C.; Schaap, J.; Jewbali, L. S.; Smits, P. C.; Patel, R. S.; Aujayeb, A.; Ripley, D. P.; Saxena, M.; Spinner, C.; McCann, G. P.; Moss, A. J.; Parker, E.; Borgmann, S.; Tessitore, E.; Rieg, S.; Kearney, M. T.; Byrom-Goulthorp, R.; Hower, M.; Al-Ali, A. K.; Alshehri, A. M.; Alnafie, A. N.; Alshahrani, M.; Almubarak, Y. A.; Al-Muhanna, F. A.; Al-Rubaish, A. M.; Hanses, F.; Shore, A. C.; Ball, C.; Anning, C. M.; Rüthrich, M. M.; Nierop, P. R.; Vehreschild, Mjgt, Heymans, S. R. B.; Henkens, Mthm, Raafs, A. G.; van der Horst, I. C. C.; van Bussel, B. C. T.; Magdelijns, F. J. H.; Lanznaster, J.; Kopylov, P. Y.; Blagova, O. V.; Wille, K.; Pinto, Y. M.; Offerhaus, J. A.; Bleijendaal, H.; Piepel, C.; ten Berg, J. M.; Bor, W. L.; Maarse, M.; Römmele, C.; Tio, R. A.; Sturkenboom, N. H.; Tometten, L.; den Uil, C. A.; Scholte, N. T. B.; Groenendijk, A. L.; Dolff, S.; Zijlstra, L. E.; Hilt, A. D.; von Bergwelt-Baildon, M.; Groenemeijer, B. E.; Merle, U.; van der Zee, P. M.; van Beek, E. A.; Rothfuss, K.; Tjong, F. V. Y.; van der Lingen, A. C. J.; Kolk, M. Z. H.; Isberner, N.; Monraats, P. S.; Magro, M.; Hermans, W. R. M.; Kochanek, M.; Captur, G.; Thomson, R. J.; Nadalin, S.; Linssen, G. C. M.; Veneman, T.; Zaal, R.; Degenhardt, C.; Martens, Fmac, Badings, E. A.; Strauss, R.; Zaman, A. G.; Alkhalil, M.; Prasad, S.; Grüner, B.; Haerkens-Arends, H. E.; Eberwein, L.; Dark, P.; Lomas, D.; vom Dahl, J.; Verschure, D. O.; Hellwig, K.; Mosterd, A.; Rauschning, D.; van der Heijden, D. J.; Neufang, M.; van Hessen, M.; Raichle, C.; Montagna, L.; Mazzilli, S. G.; Bianco, M.; Westhoff, T.; Shafiee, A.; Hedayat, B.; Saneei, E.; Porhosseini, H.; Jensen, B.; Gabriel, L.; Er, A. G.; Kietselaer, Bljh, Schubert, J.; Timmermans, P.; Messiaen, P.; Friedrichs, A.; van den Brink, F. S.; Woudstra, P.; Trauth, J.; Ribeiro, M. I. A.; de With, K.; van der Linden, Mmjm, Kielstein, J. T.; Macías Ruiz, R.; Guggemos, W.; Hellou, E.; Markart, P.; van Kesteren, H. A. M.; Heigener, D.; de Vries, J. K.; Stieglitz, S.; Baltazar, J. B.; Voigt, I.; van de Watering, D. J.; Milovanovic, M.; Redón, J.; Forner, M. J.; Rüddel, J.; Wu, K. W.; Nattermann, J.; Veldhuis, L. I.; Westendorp, I. C. D.; Riedel, C.; Kwakkel-van Erp, J. M.; van Ierssel, S.; van Craenenbroeck, E. M.; Walter, L.; de Sutter, J.; Worm, M.; Drost, J. T.; Moriarty, A.; Salah, R.; Charlotte, N.; van Boxem, A. J. M.; Dorman, H. G. R.; Reidinga, A. C.; van der Meer, P.; Wierda, E.; van Veen, Hpaa, Delsing, C. E.; Meijs, M. F. L.; van de Wal, R. M. A.; Weytjens, C.; Hermanides, R. S.; Emans, M. E.; al-Windy, N. Y. Y.; Koning, A. M. H.; Schellings, Daam, Anthonio, R. L.; Bucciarelli-Ducci, C.; Caputo, M.; Westendorp, P. H. M.; Kuijper, A. F. M.; van Ofwegen-Hanekamp, C. E. E.; Persoon, A. M.; Seelig, J.; van der Harst, P.; Siebelink, H. J.; van Smeden, M.; Williams, S.; Pilgram, L.; van Gilst, W. H.; Tieleman, R. G.; Williams, B.; Asselbergs, F. W..
Preprint in English | Other preprints | ID: ppcovidwho-294508


Aims Patients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality. Method and results We used data from the CAPACITY-COVID registry and LEOSS study. Multivariable Poisson regression models were fitted to assess the association between different types of pre-existent heart disease and in-hospital mortality. 16,511 patients with COVID-19 were included (21.1% aged 66 – 75 years;40.2% female) and 31.5% had a history of heart disease. Patients with heart disease were older, predominantly male and often had other comorbid conditions when compared to those without. Mortality was higher in patients with cardiac disease (29.7%;n=1545 versus 15.9%;n=1797). However, following multivariable adjustment this difference was not significant (adjusted risk ratio (aRR) 1.08 [95% CI 1.02 – 1.15;p-value 0.12 (corrected for multiple testing)]). Associations with in-hospital mortality by heart disease subtypes differed considerably, with the strongest association for heart failure aRR (1.19 [1.10 – 1.30];p-value <0.018) particularly for severe NYHA III/IV) heart failure (aRR 1.41 [95% CI 1.20 – 1.64;p-value <0.018]. None of the other heart disease subtypes, including ischemic heart disease, remained significant after multivariable adjustment. Serious cardiac complications were diagnosed in <1% of patients. Conclusion Considerable heterogeneity exists in the strength of association between heart disease subtypes and in-hospital mortality. Of all patients with heart disease, those with heart failure are at greatest risk of death when hospitalized with COVID-19. Serious cardiac complications are rare.

Qual Life Res ; 30(8): 2123-2135, 2021 Aug.
Article in English | MEDLINE | ID: covidwho-1509285


BACKGROUND: Veno-venous extracorporeal membrane oxygenation (VV-ECMO) has been used successfully for the past decade in adult patients with acute respiratory distress syndrome (ARDS) refractory to conventional ventilatory support. However, knowledge of the health-related quality of life (HRQoL) in VV-ECMO patients is still limited. Thus, this study aimed to provide a comprehensive overview of the HRQoL following VV-ECMO support in ARDS patients. METHODS: A systematic search was performed on PubMed and Web of Science databases from January 1st, 2009 to October 19th, 2020. Studies reporting on HRQoL following VV-ECMO for ARDS in adults were included. Two authors independently selected studies, extracted data, and assessed methodological quality. RESULTS: Eight studies were eligible for inclusion, consisting of seven observational studies and one randomized controlled trial (total N = 441). All eight studies had a quantitative design and reported 265 VV-ECMO survivors to have a reduced HRQoL compared to a generally healthy population. Follow-up time varied between six months to three years. Additionally, only four studies (total N = 335) compared the HRQoL of VV-ECMO (N = 159) to conventionally treated survivors (N = 176), with one study showing a significantly better HRQoL in VV-ECMO survivors, while three studies were stating comparable HRQoL across groups. Notably, most survivors in these studies appeared to experience varying degrees of anxiety, depression, and post-traumatic stress disorder (PTSD). CONCLUSIONS: ARDS survivors supported by VV-ECMO have a decline in HRQoL and suffered from physical and psychological impairments. This HRQoL reduction is comparable or even better to the HRQoL in conventionally treated ARDS survivors.

Extracorporeal Membrane Oxygenation/psychology , Quality of Life/psychology , Respiratory Distress Syndrome/therapy , Adult , Cross-Sectional Studies , Extracorporeal Membrane Oxygenation/methods , Health Status , Humans , Respiratory Distress Syndrome/psychology , Survivors , Treatment Outcome